Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
NeuroActiva, Inc. logo — Our goal is to make Alzheimer's disease a disease of the pas...

NeuroActiva, Inc.

Our goal is to make Alzheimer's disease a disease of the past.

United States United States 2 employees Biotechnology

General Information

Company Name NeuroActiva, Inc.
Location United States United States +5
Employees 2
Industries Biotechnology
Social

Get notified when NeuroActiva, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About NeuroActiva, Inc.

NeuroActiva, Inc. is a clinical-stage biopharmaceutical company with the mission to combat Alzheimer's disease. As a subsidiary of Biomed Industries, Inc., the company focuses on developing and bringing to market innovative drugs for Alzheimer's treatment. Their lead candidate, NA-831 (Traneurocin), has shown promising safety and efficacy in Phase 2A trials, with plans for Phase 2B/3 in 2022. Another potential breakthrough is NA-704 (Vineurocin), designed to regulate cell growth and DNA synthesis in nerve cells, catering to Alzheimer's and other neurological disorders. Moreover, NeuroActiva has introduced the MICROS Controlled Release Infusion System, a cutting-edge intravenous drug delivery system approved for marketing in the USA. This diversified pipeline and innovative technology signify the company's potential for addressing unmet medical needs in the biotechnology sector.

Taxonomy: Biopharmaceutical drug developer, Pharmaceutical company, Alzheimer's disease, Neuroprotection, Neurogenesis, New drug discovery, Parkinson's disease, ALS (amyotrophic lateral sclerosis), Multiple sclerosis, FDA affairs, Regulatory affairs, Clinical trials, NeuroActiva, Inc., MICROS Controlled Release Infusion System

No funding data available for NeuroActiva, Inc. yet.

Get notified when NeuroActiva, Inc. raises funding

NeuroActiva, Inc. Alternatives & Competitors

NeuroActiva, Inc. vs
Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. Canada

Life sciences company focused on the research and clinical development of therapies for the treatmen...

Post Ipo Equity
27 employees
Biotechnology, Life Sciences
NeuroActiva, Inc. vs
F2G
F2G United Kingdom

The rare fungal disease company

Unknown
95 employees
Biotechnology, Health Care
NeuroActiva, Inc. vs
Hepion Pharmaceuticals
Hepion Pharmaceuticals United States

Hepion Pharmaceuticals, Inc. is not affiliated in any way with Wire™ or Wire Swiss GmbH in any capac...

Post Ipo Debt
7 employees
Biotechnology, Life Sciences

FAQ About NeuroActiva, Inc.

Our goal is to make Alzheimer's disease a disease of the past.
NeuroActiva, Inc. is headquartered in United States.
NeuroActiva, Inc. operates in the following industries: Biotechnology.
NeuroActiva, Inc. has approximately 2 employees.
Top alternatives and competitors to NeuroActiva, Inc. include Cardiol Therapeutics Inc. , F2G, Hepion Pharmaceuticals, Neuronascent, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NeuroActiva, Inc. and Cardiol Therapeutics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors NeuroActiva, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy